← All trials
NCT05096481
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2022
- Primary completion
- Sep 30, 2026
- Completion date
- Sep 30, 2028
- First posted
- Oct 27, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ohio State UniversityLead sponsor
- Duke UniversityStudy chair
- Ohio State UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.